PriceTargets.com logo

Haleon - HLN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $364.00
  • Forecasted Upside: 4,366.26%
  • Number of Analysts: 14
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$8.15 As of 06/9/2023 01:00 AM ET
▼ -0.1 (-1.21%)

This chart shows the closing price for HLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haleon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLN

Analyst Price Target is $364.00
▲ +4,366.26% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Haleon in the last 3 months. The average price target is $364.00, with a high forecast of $364.00 and a low forecast of $364.00. The average price target represents a 4,366.26% upside from the last price of $8.15.

This chart shows the closing price for HLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 14 polled investment analysts is to hold stock in Haleon. This rating has held steady since February 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2023Stifel NicolausInitiated CoverageHoldLow
4/6/2023ArgusUpgradeHold ➝ BuyLow
4/4/2023Sanford C. BernsteinInitiated CoverageOutperformLow
2/23/2023InvestecInitiated CoverageSellLow
1/31/2023BarclaysBoost TargetGBX 360 ➝ GBX 364Low
1/6/2023Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
12/7/2022BarclaysUpgradeEqual Weight ➝ OverweightLow
11/11/2022BarclaysLower TargetGBX 347 ➝ GBX 298Low
9/28/2022ArgusInitiated CoverageHoldLow
8/19/2022Morgan StanleyInitiated CoverageEqual WeightLow
8/15/2022Royal Bank of CanadaInitiated CoverageSector PerformLow
7/29/2022Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
7/25/2022The Goldman Sachs GroupInitiated CoverageBuyLow
7/25/2022Credit Suisse GroupInitiated CoverageOutperformLow
7/25/2022Bank of AmericaInitiated CoverageBuyLow
7/25/2022BarclaysInitiated CoverageEqual WeightLow
7/25/2022Jefferies Financial GroupInitiated CoverageHoldLow
7/25/2022JPMorgan Chase & Co.Initiated CoverageUnderweightLow
7/25/2022CitigroupInitiated CoverageBuyLow
(Data available from 6/9/2018 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/11/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/11/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/10/2023
  • 14 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/9/2023
  • 13 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2023
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2023
  • 13 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2023
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/9/2023

Current Sentiment

  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Haleon logo
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Read More

Today's Range

Now: $8.15
Low: $8.14
High: $8.20

50 Day Range

MA: $8.61
Low: $8.07
High: $9.00

52 Week Range

Now: $8.15
Low: $5.59
High: $9.05

Volume

2,252,130 shs

Average Volume

4,394,549 shs

Market Capitalization

$37.63 billion

P/E Ratio

N/A

Dividend Yield

0.73%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Haleon?

The following equities research analysts have issued research reports on Haleon in the last twelve months: Argus, Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Investec, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for HLN.

What is the current price target for Haleon?

1 Wall Street analysts have set twelve-month price targets for Haleon in the last year. Their average twelve-month price target is $364.00, suggesting a possible upside of 4,366.3%. Barclays PLC has the highest price target set, predicting HLN will reach $364.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $364.00 for Haleon in the next year.
View the latest price targets for HLN.

What is the current consensus analyst rating for Haleon?

Haleon currently has 2 sell ratings, 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HLN, but not buy more shares or sell existing shares.
View the latest ratings for HLN.

What other companies compete with Haleon?

Other companies that are similar to Haleon include IDEXX Laboratories, Alcon, Centene, Seagen and GE HealthCare Technologies. Learn More about companies similar to Haleon.

How do I contact Haleon's investor relations team?

The company's listed phone number is 44-19-3282-2000 and its investor relations email address is in[email protected]. The official website for Haleon is www.haleon.com. Learn More about contacing Haleon investor relations.